# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY AND INSTRUMENT COMBINATION TEMPLATE

A. 510(k) Number: k062058

C. Measurand: Glucose

E. Applicant: Bayer HealthCare, LLC.

F. Proprietary and Established Names: Ascensia $^ \mathrm { \textregistered }$ CONTOUR $^ \mathrm { \textregistered }$ Blood Glucose Monitoring System

# G. Regulatory Information:

1. Regulation section: 21 CFR $\ S$ 862.1345, Glucose Test System

2. Classification: Class II

3. Product code: NBW, LFR

4. Panel: 75 (Clinical Chemistry)

# H. Intended Use:

1. Intended use(s): See indications for use below.

2. Indication(s) for use: The Ascensia $^ \mathrm { \textregistered }$ CONTOUR $^ \mathrm { \textregistered }$ Blood Glucose Monitoring System is used for the measurement of glucose in whole blood. The Ascensia $^ \mathrm { \textregistered }$ CONTOUR $^ \mathrm { \textregistered }$ Blood Glucose Monitoring System is an over-the-counter (OTC) device used by persons with diabetes and by healthcare professionals in home settings and in healthcare facilities. The

Ascensia $^ \mathrm { \textregistered }$ CONTOUR $^ \mathrm { \textregistered }$ Blood Glucose Monitoring System is indicated for use with capillary, venous, and arterial whole blood samples and neonatal blood samples. Capillary samples may be drawn from the fingertip, palm, forearm, and in the case of neonates, the heel. The frequent monitoring of blood glucose is an adjunct to the care of persons with diabetes.

3. Special conditions for use statement(s): For over-the-counter use and by healthcare professionals

4. Special instrument requirements: Ascensia $^ \mathrm { \textregistered }$ CONTOUR $^ \mathrm { \textregistered }$ Blood Glucose Monitoring System

# I. Device Description:

The Ascensia $^ \mathrm { \textregistered }$ CONTOUR $^ \mathrm { \textregistered }$ Blood Glucose Monitoring System is used for the measurement of glucose in whole blood. The system contains a blood glucose meter, a bottle of strips, a bottle of normal control solution, a lancing device and lancets, and instructions for use.

# J. Substantial Equivalence Information:

1. Predicate device name(s): Ascensia $^ \mathrm { \textregistered }$ CONTOUR $^ \mathrm { \textregistered }$ Diabetes Care System

2. Predicate 510(k) number(s): k023657, k060470

3. Comparison with predicate:

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Detection Method</td><td rowspan=1 colspan=1>Amperometry</td><td rowspan=1 colspan=1>Amperometry</td></tr><tr><td rowspan=1 colspan=1>Enzyme</td><td rowspan=1 colspan=1>Glucose Dehydrogenase(FAD)</td><td rowspan=1 colspan=1>Glucose Dehydrogenase(FAD)</td></tr><tr><td rowspan=1 colspan=1>Sample Volume</td><td rowspan=1 colspan=1>0.6 μL</td><td rowspan=1 colspan=1>0.6 μL</td></tr><tr><td rowspan=1 colspan=1>Test Range</td><td rowspan=1 colspan=1>10 - 600 mg/dL</td><td rowspan=1 colspan=1>10 - 600 mg/dL</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Test Time</td><td rowspan=1 colspan=1>5 seconds</td><td rowspan=1 colspan=1>15 seconds</td></tr><tr><td rowspan=1 colspan=1>Tests Stored in Memory</td><td rowspan=1 colspan=1>480</td><td rowspan=1 colspan=1>240</td></tr><tr><td rowspan=1 colspan=1>Correction factors</td><td rowspan=1 colspan=1>Added correctingalgorithms</td><td rowspan=1 colspan=1>None.</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

ISO 15197: In vitro diagnostic test systems - Requirements for blood-glucose monitoring systems for self-testing in managing diabetes mellitus.

# L. Test Principle:

Once a whole blood sample is applied to the sample chamber of the test strip, glucose measurement commences. Glucose measurement is based on electrical potential caused by the reaction of glucose with the reagents contained on the strip’s electrodes. The current resulting from this enzymatic reaction is measured and converted to glucose concentration by the meter.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility: With-in Run Precision: Human whole blood samples with hematocrit of $3 5 \% { - } 5 0 \%$ were collected in tubes with sodium heparin anticoagulant. Using a $10 \%$ aqueous glucose solution, blood samples were prepared within the following ranges prescribed in ISO 15197 section 7.2.2.2:

$3 0 { \cdot } 5 0 \ \mathrm { \ m g / d L }$ (actual value $= 4 1 . 3$ mg/dL) $5 1 { \mathrm { - } } 1 1 0 \ \mathrm { m g / d L }$ (actual value $= 9 9 . 2$ mg/dL) $1 1 1 - 1 5 0 \mathrm { m g / d L }$ (actual value $= I I 9 . 5$ mg/dL) $1 5 1 { - } 2 5 0 \mathrm { m g / d L }$ (actual value $= 2 0 0 . 0$ mg/dL) $2 5 1 { \mathrm { - } } 4 0 0 \ \mathrm { m g / d L }$ (actual value $=$ 325.5 mg/dL)

A total of ten blood glucose meters were used to test one test sensor lot with the above blood samples. One bottle of test sensors was assigned to each instrument at the start of the study. One operator performed all the testing. Ten tests were performed with each blood sample on each instrument. Results are summarized below.

Pooled Statistics for the Shogun System   

<table><tr><td rowspan=1 colspan=1>Level(mg/dL)</td><td rowspan=1 colspan=1>GrandMean(mg/dL)</td><td rowspan=1 colspan=1>PooledVariance</td><td rowspan=1 colspan=1>Pooled%CV</td></tr><tr><td rowspan=1 colspan=1>40*</td><td rowspan=1 colspan=1>38</td><td rowspan=1 colspan=1>3.7</td><td rowspan=1 colspan=1>4.8</td></tr><tr><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>101</td><td rowspan=1 colspan=1>26.8</td><td rowspan=1 colspan=1>5.1</td></tr><tr><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>118</td><td rowspan=1 colspan=1>19.4</td><td rowspan=1 colspan=1>3.7</td></tr><tr><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>205</td><td rowspan=1 colspan=1>48.1</td><td rowspan=1 colspan=1>3.3</td></tr><tr><td rowspan=1 colspan=1>325</td><td rowspan=1 colspan=1>326</td><td rowspan=1 colspan=1>139.7</td><td rowspan=1 colspan=1>3.6</td></tr></table>

\*Pooled SD=1.9

Day-to-Day Precision:

One bottle of Ascensia Contour test sensors was assigned to each of ten Ascensia Contour instruments. On each day of ten consecutive working days (no testing on weekends), one test sensor was tested on each instrument with each level of Low, Normal and High Ascensia Microfill control solution. One operator performed all of the testing.

The following summarizes the specific materials used in the study:

<table><tr><td colspan="3">Control</td></tr><tr><td>Level</td><td>Lot #</td><td>Control Ranges</td></tr><tr><td>Low</td><td>1197</td><td>32 - 44 mg/dL</td></tr><tr><td>Normal</td><td>V99216</td><td>99 - 136 mg/dL</td></tr><tr><td>High</td><td>V99207</td><td>288  398 mg/dL</td></tr></table>

Results from the precision evaluation are summarized in the table below.

Pooled Statistics for the Shogun System   

<table><tr><td rowspan=1 colspan=1>ControlSolution</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>GrandMean</td><td rowspan=1 colspan=1>PooledVariance</td><td rowspan=1 colspan=1>Pooled%CV</td></tr><tr><td rowspan=1 colspan=1>Low*</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>1.7</td></tr><tr><td rowspan=1 colspan=1>Normal</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>124</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>1.3</td></tr><tr><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>368</td><td rowspan=1 colspan=1>14.9</td><td rowspan=1 colspan=1>1.0</td></tr></table>

\*Pooled SD=0.7

b. Linearity/assay reportable range:

To establish the linearity of the Contour system throughout the entire reportable range of 10 to $6 0 0 \mathrm { m g / d L }$ , data from three studies were combined. In one study, blood with $40 \%$ hematocrit was adjusted to plasma glucose concentrations of 10, 20, 30, 40, 50, and $6 0 \mathrm { m g / d L }$ and tested with four Contour lots, $\mathrm { n } { = } 1 6$ per lot. In a second study, 12 Contour lots were tested with blood adjusted to 50, 120, and $3 0 0 \mathrm { m g / d L }$ glucose, $\mathbf { n } =$ 24 per lot. In a third study, 10 Contour lots were tested with blood adjusted to 43, 62, 127, 331, and $6 0 9 { \mathrm { m g / d L } }$ , ${ \mathfrak { n } } = 2 0$ per lot. Regression analysis (using the proportionally weighted least-squares model) conducted with the combined lot means from all three studies $( \mathrm { N } = 1 1 0 )$ ) yields the following statistics:

<table><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>110</td></tr><tr><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>0.987</td></tr><tr><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>-0.7</td></tr><tr><td rowspan=1 colspan=1>r2}$</td><td rowspan=1 colspan=1>0.996</td></tr></table>

c. Traceability, Stability, Expected values (controls, calibrators, or methods): Traceability is referenced to the NIST SRM 917a (dry D-glucose).

d. Detection limit:

$1 0 \mathrm { m g / d L }$ . This level was determined to be detectable by the linearity study (above) and by the hematocrit sensitivity study (see Analytical Specificity below).

e. Analytical specificity:

The interference effect of oxidizable substances (acetaminophen, uric acid, ascorbic acid) were tested at the following levels and were found to meet the sponsors acceptance criteria that the bias at the following limiting plasma concentrations be

less than $1 5 \%$

Bilirubin: $2 0 \mathrm { m g / d L }$ Acetaminophen: $2 0 \mathrm { m g / d L }$ Uric Acid: $1 5 \mathrm { m g / d L }$ Ascorbic Acid: $5 \mathrm { m g / d L }$

To verify that the Contour system provides accurate results at the lower end of the reportable range (where actual clinical specimens are rare and clinical trials cannot be expected to provide extensive data), a dose response study was conducted with blood at three hematocrit levels $40 \%$ , $5 5 \%$ , and $70 \%$ ) adjusted to plasma glucose concentrations of 10, 20, 30, 40, 50, and $6 0 \mathrm { m g / d L }$ . Four Contour lots (SN05M26A, SN06A06C, 6EC3C01 and 6EC3C02) were each tested with eight Contour meters, two replicates per meter, for a total of 16 replicates per lot per sample. Readings were compared to YSI plasma glucose. The sponsor’s acceptance criterion was $9 5 \%$ of results within $\pm 1 5 \mathrm { m g / d L }$ of the YSI mean which $100 \%$ of the samples met. Regression statistics are summarized below.

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>40% Hematocrit</td><td rowspan=1 colspan=1>55% Hematocrit</td><td rowspan=1 colspan=1>70% Hematocrit</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>384</td><td rowspan=1 colspan=1>384</td><td rowspan=1 colspan=1>384</td></tr><tr><td rowspan=1 colspan=1>Regressionequation</td><td rowspan=1 colspan=1>y = 0.880(x) + 1.1</td><td rowspan=1 colspan=1>y = 0.788(x) + 10.1</td><td rowspan=1 colspan=1>y = 0.892(x) + 7.3</td></tr><tr><td rowspan=1 colspan=1>2r</td><td rowspan=1 colspan=1>0.985</td><td rowspan=1 colspan=1>0.956</td><td rowspan=1 colspan=1>0.975</td></tr></table>

To test the accuracy of the hematocrit correction algorithm, three lots, ${ \mathfrak { n } } = 2 0$ per lot, with blood adjusted to hematocrit levels of $0 \%$ (pure plasma), $20 \%$ , $3 5 \%$ , $45 \%$ , $5 5 \%$ , and $70 \%$ at glucose concentrations of 80 and $3 5 0 \mathrm { m g / d L }$ were tested. The sponsor’s acceptance criteria were was a difference between mean at $45 \%$ hematocrit (normal) and means at $0 \%$ and $70 \%$ hematocrit $< 1 0 \%$ or $7 . 5 \ : \mathrm { m g / d L }$ . Results are summarized below.

Hematocrit Effect   

<table><tr><td rowspan=1 colspan=3></td><td rowspan=1 colspan=1>0% Hct</td><td rowspan=1 colspan=1>20% Hct</td><td rowspan=1 colspan=1>35% Hct</td><td rowspan=1 colspan=1>45% Hct</td><td rowspan=1 colspan=1>55% Hct</td><td rowspan=1 colspan=1>70% Hct</td></tr><tr><td rowspan=8 colspan=1>PercentDeviationfrom 45%Hct</td><td rowspan=4 colspan=1>80mg/dL</td><td rowspan=1 colspan=1>SN05L10C</td><td rowspan=1 colspan=1>-1.8%</td><td rowspan=1 colspan=1>2.3%</td><td rowspan=1 colspan=1>2.2%</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>-1.4%</td><td rowspan=1 colspan=1>-2.8%</td></tr><tr><td rowspan=1 colspan=1>SN05L10D</td><td rowspan=1 colspan=1>-0.5%</td><td rowspan=1 colspan=1>4.1%</td><td rowspan=1 colspan=1>4.7%</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>-3.1%</td><td rowspan=1 colspan=1>-9.5%</td></tr><tr><td rowspan=1 colspan=1>SN05L15</td><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>5.4%</td><td rowspan=1 colspan=1>6.3%</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>-2.7%</td><td rowspan=1 colspan=1>-8.3%</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>-0.2%</td><td rowspan=1 colspan=1>3.9%</td><td rowspan=1 colspan=1>4.4%</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>-2.4%</td><td rowspan=1 colspan=1>-6.8%</td></tr><tr><td rowspan=4 colspan=1>350mg/dL</td><td rowspan=1 colspan=1>SN05L10C</td><td rowspan=1 colspan=1>-1.9%</td><td rowspan=1 colspan=1>-4.2%</td><td rowspan=1 colspan=1>-0.4%</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.5%</td><td rowspan=1 colspan=1>-4.4%</td></tr><tr><td rowspan=1 colspan=1>SN05L10D</td><td rowspan=1 colspan=1>-1.4%</td><td rowspan=1 colspan=1>-3.4%</td><td rowspan=1 colspan=1>1.0%</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.9%</td><td rowspan=1 colspan=1>-3.8%</td></tr><tr><td rowspan=1 colspan=1>SN05L15</td><td rowspan=1 colspan=1>0.1%</td><td rowspan=1 colspan=1>-2.8%</td><td rowspan=1 colspan=1>0.9%</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>-3.3%</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>-1.1%</td><td rowspan=1 colspan=1>-3.5%</td><td rowspan=1 colspan=1>0.5%</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>-3.8%</td></tr></table>

To test the accuracy of the hematocrit correction algorithm at higher levels closer to the claimed range, three lots, ${ \mathfrak { n } } = 5$ per lot, with blood adjusted to hematocrit levels of $0 \%$ (pure plasma), $20 \%$ , $45 \%$ , $60 \%$ , and $70 \%$ at glucose concentrations of 450 and

$5 5 0 \mathrm { m g / d L }$ were tested. The sponsor’s acceptance criteria were was a difference between mean at $45 \%$ hematocrit (normal) and means at $0 \%$ and $70 \%$ hematocrit $< 1 0 \%$ or $7 . 5 \ : \mathrm { m g / d L }$ . Results are summarized below.

<table><tr><td rowspan=1 colspan=3></td><td rowspan=1 colspan=1>0% Hct</td><td rowspan=1 colspan=1>20%Hct</td><td rowspan=1 colspan=1>45%Hct</td><td rowspan=1 colspan=1>60%Hct</td><td rowspan=1 colspan=1>70%Hct</td></tr><tr><td rowspan=8 colspan=1>PercentDeviationfrom 45%Hct</td><td rowspan=4 colspan=1>450mg/dL</td><td rowspan=1 colspan=1>6JC3C07</td><td rowspan=1 colspan=1>5.2</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>3.7</td><td rowspan=1 colspan=1>2.5</td></tr><tr><td rowspan=1 colspan=1>6JC3C05</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>0.3</td></tr><tr><td rowspan=1 colspan=1>6HC3C09</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>0.5</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>1.1</td></tr><tr><td rowspan=4 colspan=1>550mg/dL</td><td rowspan=1 colspan=1>6JC3C07</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>-2.8</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>1.3</td></tr><tr><td rowspan=1 colspan=1>6JC3C05</td><td rowspan=1 colspan=1>4.8</td><td rowspan=1 colspan=1>-0.3</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>-0.3</td></tr><tr><td rowspan=1 colspan=1>6HC3C09</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>-1.2</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>-1.1</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>-1.4</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>-0.1</td></tr></table>

In addition to testing compounds that are known to interfere with electrochemical glucose monitoring systems (above), testing was also conducted with a variety of common compounds found in medications or food or occurring naturally in the blood. The following substances were tested and found to either have no effect trend at any concentration or to have a limiting concentration (interpolated or extrapolated concentration creating a bias of $1 5 \%$ at either 80 or $3 0 0 \mathrm { m g / d L }$ glucose) that was significantly higher than the upper limit of the therapeutic or reference range.

<table><tr><td rowspan=1 colspan=1>Compound</td><td rowspan=1 colspan=1>High Normal/TherapeuticConcentration</td><td rowspan=1 colspan=1>Test Levels</td><td rowspan=1 colspan=1>LimitingConcentration</td></tr><tr><td rowspan=1 colspan=1>Acetone</td><td rowspan=1 colspan=1>2 mg/dL</td><td rowspan=1 colspan=1>17.34.67</td><td rowspan=1 colspan=1>N.S.</td></tr><tr><td rowspan=1 colspan=1>Acetylsalicylic Acid</td><td rowspan=1 colspan=1>2- 10 mg/dL</td><td rowspan=1 colspan=1>8, 17, 34, 67</td><td rowspan=1 colspan=1>74 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Albumin</td><td rowspan=1 colspan=1>3.4-5.4 g/L</td><td rowspan=1 colspan=1>17, 32, 56 g/L</td><td rowspan=1 colspan=1>N.S.</td></tr><tr><td rowspan=1 colspan=1>β-hydroxybutyricAcid</td><td rowspan=1 colspan=1>32 mg/dL</td><td rowspan=1 colspan=1>14, 28, 56</td><td rowspan=1 colspan=1>N.S.</td></tr><tr><td rowspan=1 colspan=1>Caffeine</td><td rowspan=1 colspan=1>1.5 mg/dL</td><td rowspan=1 colspan=1>1.7, 3.4, 6.7</td><td rowspan=1 colspan=1>N.S.</td></tr><tr><td rowspan=1 colspan=1>Creatinine</td><td rowspan=1 colspan=1>1.5 mg/dL</td><td rowspan=1 colspan=1>8.17,34</td><td rowspan=1 colspan=1>N.S.</td></tr><tr><td rowspan=1 colspan=1>Dobutamine</td><td rowspan=1 colspan=1>0.07 mg/dL</td><td rowspan=1 colspan=1>8.17.34</td><td rowspan=1 colspan=1>16 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Dopamine</td><td rowspan=1 colspan=1>0.03 mg/dL</td><td rowspan=1 colspan=1>1.1.2.2. 4.5. 9.0</td><td rowspan=1 colspan=1>3.7 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Ethanol</td><td rowspan=1 colspan=1>300 mg/dL</td><td rowspan=1 colspan=1>98, 196, 392</td><td rowspan=1 colspan=1>N.S.</td></tr><tr><td rowspan=1 colspan=1>Fructose</td><td rowspan=1 colspan=1>7 mg/dL</td><td rowspan=1 colspan=1>84, 168, 336</td><td rowspan=1 colspan=1>N.S.</td></tr><tr><td rowspan=1 colspan=1>Gentisic Acid</td><td rowspan=1 colspan=1>5.0 mg/dL</td><td rowspan=1 colspan=1>28, 56, 112</td><td rowspan=1 colspan=1>15 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Glipizide</td><td rowspan=1 colspan=1>0.8 mg/dL</td><td rowspan=1 colspan=1>0.8, 1.7, 3.4</td><td rowspan=1 colspan=1>8.4 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Glucosamine</td><td rowspan=1 colspan=1>30 mg/dL</td><td rowspan=1 colspan=1>56,112,224</td><td rowspan=1 colspan=1>N.S.</td></tr><tr><td rowspan=1 colspan=1>Glutathione</td><td rowspan=1 colspan=1>68.5 ± 10.7 mg/dL in RBC</td><td rowspan=1 colspan=1>35, 70, 140, 280</td><td rowspan=1 colspan=1>28.8 mg/dL in plasma</td></tr><tr><td rowspan=1 colspan=1>Glyburide</td><td rowspan=1 colspan=1>0.4 mg/dL</td><td rowspan=1 colspan=1>0.6, 1.1, 2.2</td><td rowspan=1 colspan=1>N.S.</td></tr><tr><td rowspan=1 colspan=1>Heparin</td><td rowspan=1 colspan=1>4000 units/dL</td><td rowspan=1 colspan=1>3808, 6048, 10528</td><td rowspan=1 colspan=1>N.S.</td></tr><tr><td rowspan=1 colspan=1>Ibuprofen</td><td rowspan=1 colspan=1>4.2 mg/dL</td><td rowspan=1 colspan=1>11,22, 45</td><td rowspan=1 colspan=1>N.S.</td></tr><tr><td rowspan=1 colspan=1>L-Dopa</td><td rowspan=1 colspan=1>0.3 mg/dL</td><td rowspan=1 colspan=1>0.3, 0.7, 1.3</td><td rowspan=1 colspan=1>1.9 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Metformin</td><td rowspan=1 colspan=1>4.0 mg/dL</td><td rowspan=1 colspan=1>1.1, 2.2, 4.5</td><td rowspan=1 colspan=1>N.S.</td></tr><tr><td rowspan=1 colspan=1>Methyldopa</td><td rowspan=1 colspan=1>0.75 mg/dL</td><td rowspan=1 colspan=1>0.8, 1.7, 3.4</td><td rowspan=1 colspan=1>3.6 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Naproxen</td><td rowspan=1 colspan=1>12 mg/dL</td><td rowspan=1 colspan=1>28, 56, 112</td><td rowspan=1 colspan=1>208 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Precose</td><td rowspan=1 colspan=1>6 mg/dL</td><td rowspan=1 colspan=1>5.6, 11.2, 22.4</td><td rowspan=1 colspan=1>N.S.</td></tr><tr><td rowspan=1 colspan=1>Sodium lactate</td><td rowspan=1 colspan=1>20 mg/dL</td><td rowspan=1 colspan=1>7,14,58, 112</td><td rowspan=1 colspan=1>N.S.</td></tr><tr><td rowspan=1 colspan=1>Sodium salicylate</td><td rowspan=1 colspan=1>30 mg/dL</td><td rowspan=1 colspan=1>28, 56, 112</td><td rowspan=1 colspan=1>41 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Sucrose</td><td rowspan=1 colspan=1>2.7 mg/dL</td><td rowspan=1 colspan=1>5.6, 11.2, 22.4</td><td rowspan=1 colspan=1>N.S.</td></tr><tr><td rowspan=1 colspan=1>Tetracycline</td><td rowspan=1 colspan=1>0.4 mg/dL</td><td rowspan=1 colspan=1>1.1, 2.2, 4.5</td><td rowspan=1 colspan=1>N.S.</td></tr><tr><td rowspan=1 colspan=1>Triglycerides</td><td rowspan=1 colspan=1>190 mg/dL</td><td rowspan=1 colspan=1>2580, 5160</td><td rowspan=1 colspan=1>5070 mg/dL</td></tr></table>

It was found that the anticoagulant EDTA, especially when occurring at concentrations higher than normal due to under-filling an EDTA tube, is electrochemically active enough to produce a significant negative bias. For this reason, EDTA tubes will be restricted in the Limitations section of the labeling.

To investigate the effect of altitude on the system, three lots of reagent were tested across eight (8) meters both inside and outside a hypoxic chamber simulating an altitude of 12,095 feet. A maximum of three (3) repetitions on each meter were performed $( \mathrm { n } { = } 2 4 )$ ). Time limitations in some cases allowed for only two (2) repetitions on each meter $\mathrm { ( n = 1 6 }$ ). Whole blood samples with plasma glucose values of 50, 100, and $4 0 0 \mathrm { m g / d L }$ were tested in the above manner, at both $40 \%$ and $60 \%$ hematocrits. The acceptance criteria defined by the sponsor was $< 1 0 \%$ difference between means in the low oxygen chamber and means outside the chamber. No systematic response to altitude is seen at either Hematocrit level, and percent bias at all levels was found to be less than $10 \%$ . Therefore the system is not significantly affected by lack of atmospheric oxygen up to 12,000 feet above sea level.

f. Assay cut-off: Not Applicable.

2. Comparison studies:

# a. Method comparison with predicate device:

Fingerstick testing was conducted in two four-day studies. Data collected in four separate studies with contrived blood specimens were also used in order to bring the distribution of samples into compliance with the protocol:

Distribution of Plasma Glucose Values   

<table><tr><td rowspan=1 colspan=1>Glucose Range (mg/dL)</td><td rowspan=1 colspan=1>&lt;50</td><td rowspan=1 colspan=1>50 - 80</td><td rowspan=1 colspan=1>81 - 120</td><td rowspan=1 colspan=1>121 - 200</td><td rowspan=1 colspan=1>201 - 300</td><td rowspan=1 colspan=1>301 - 400</td><td rowspan=1 colspan=1>&gt;400</td></tr><tr><td rowspan=1 colspan=1>% of Samples</td><td rowspan=1 colspan=1>5%</td><td rowspan=1 colspan=1>15%</td><td rowspan=1 colspan=1>20%</td><td rowspan=1 colspan=1>30%</td><td rowspan=1 colspan=1>15%</td><td rowspan=1 colspan=1>10%</td><td rowspan=1 colspan=1>5%</td></tr></table>

Each specimen was tested with three Contour lots, $\mathfrak { n } = 2$ per lot for a total of six readings per specimen. After filling each bin in the ISO distribution, no additional specimens falling in that bin were included in the analysis. A total of 105 diabetic volunteers participated in the two fingerstick studies after giving informed consent, and of these donors, 74 met the distribution requirements. Since no diabetic subjects presented with extremely low or high blood glucose concentrations in either of the two fingerstick studies, readings from contrived samples were used to fill the extreme bins. Low glucose specimens were obtained from a dose response study designed to simulate neonatal specimens. In this study, blood was adjusted to glucose concentrations between 10 and $6 0 \mathrm { m g / d L }$ . To fill the lowest bin, the five lower levels (11.4, 20.5, 30.7, 40.6, and 49.8) were used (taking the two replicates generated with the first meter used with each lot). To help fill the second lowest bin, three samples at the $6 0 \mathrm { m g / d L }$ level, each with a different hematocrit $( 4 0 \%$ , $5 5 \%$ , and $70 \%$ ) were used. Data from a second study was used to obtain two samples at $6 3 \mathrm { m g / d L }$ (two testers), four samples at $3 0 1 \mathrm { m g / d L }$ (two testers, two meters per tester), two samples at 405 $\mathrm { m g / d L }$ (two testers), and one sample at $5 0 3 \mathrm { m g / d L }$ . Data from a third study was used to obtain two samples at $5 1 \mathrm { m g / d L }$ (two meters), two samples at $7 9 \mathrm { m g / d L }$ (two meters), and one sample at 201, 301, 404, and $5 5 4 \mathrm { m g / d L }$ . A fourth study was used to obtain one sample at $3 0 0 \mathrm { m g / d L }$ .

A total of 13 lots were represented in the studies. The following table summarizes the distribution of specimens and lots in each study.

<table><tr><td rowspan=1 colspan=1>Study</td><td rowspan=1 colspan=1>Lots*</td><td rowspan=1 colspan=1>&lt;50</td><td rowspan=1 colspan=1>50-80</td><td rowspan=1 colspan=1>81-120</td><td rowspan=1 colspan=1>121200</td><td rowspan=1 colspan=1>201 300</td><td rowspan=1 colspan=1>301 400</td><td rowspan=1 colspan=1>&gt;400</td></tr><tr><td rowspan=1 colspan=1>Fingerstick Study 1</td><td rowspan=1 colspan=1>A, B, C</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>29</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Fingerstick Study 2</td><td rowspan=1 colspan=1>A, D, E</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Contrived BloodStudy 1</td><td rowspan=1 colspan=1>A,F, G</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Contrived BloodStudy 2</td><td rowspan=1 colspan=1>A, D, E</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>3</td></tr><tr><td rowspan=1 colspan=1>Contrived BloodStudy 3</td><td rowspan=1 colspan=1>H, I, J</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1>Contrived BloodStudy 4</td><td rowspan=1 colspan=1>K, L, M</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>5</td></tr></table>

\* A: SN05M26A; B: SN05M26B; C: SN06A30A; D: 6FC3B01; E: 6FC3B02; F: 6EC3C01; G: 6EC3C02; H: SN06A17D; I: SN06A17E; J: SN06A17F; K: SN06A06C; L: SN06A06D; M: SN0617A

Contrived specimens were prepared with heparinized venous blood that was allowed to glycolyze to produce low glucose levels or that were supplemented with $20 \%$ glucose stock solution to produce high glucose levels. For fingerstick comparison readings, approximately $2 0 0 \mu \mathrm { L }$ of fingerstick blood was collected into a heparinized micro-collection tube. To obtain comparison glucose values, all specimens were centrifuged to separate the plasma from the blood cells, and the plasma portion was tested on the YSI STAT Plus Glucose Analyzer. Plasma glucose levels ranged from 11 to $5 5 4 ~ \mathrm { m g / d L }$ . Hematocrit levels ranged from $2 6 \%$ to $70 \%$ . The tables below include the proportionally weighted regression statistics and the percentage of readings within several error limits around the YSI plasma glucose comparison values (±5, 10, 15, and $2 0 \mathrm { m g / d L }$ for samples $< 7 5 ~ \mathrm { m g / d L }$ , $\pm 5 \%$ , $10 \%$ , $1 5 \%$ , and $20 \%$ for samples $\geq 7 5 \mathrm { m g / d L }$ ).

Contour vs. YSI Plasma Regression Equations (Proportionally Weighted Least Squares Model)   

<table><tr><td rowspan=1 colspan=1>Regression</td><td rowspan=1 colspan=1>y = 1.002(x) - 1.1</td></tr><tr><td rowspan=1 colspan=1>95% CI of Slope</td><td rowspan=1 colspan=1>0.994 to 1.010</td></tr><tr><td rowspan=1 colspan=1>95% CI of Intercept</td><td rowspan=1 colspan=1>-1.48 to -0.72</td></tr><tr><td rowspan=1 colspan=1>Syx (proportional to YSI)</td><td rowspan=1 colspan=1>7.25%</td></tr></table>

Bias at Key Glucose Levels   

<table><tr><td rowspan=1 colspan=1>Plasma Glucose</td><td rowspan=1 colspan=1>60 mg/dL</td><td rowspan=1 colspan=1>126 mg/dL</td><td rowspan=1 colspan=1>200 mg/dL</td><td rowspan=1 colspan=1>400 mg/dL</td></tr><tr><td rowspan=1 colspan=1>%Bias</td><td rowspan=1 colspan=1>-1.6%</td><td rowspan=1 colspan=1>-0.7%</td><td rowspan=1 colspan=1>-0.3%</td><td rowspan=1 colspan=1>-0.1%</td></tr></table>

Contour Accuracy Assessment (ISO 15197 Section 7.4) Contour vs. YSI Plasma Accuracy Results for Glucose Concentration < 75 mg/dL   

<table><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Within ±5mg/dL</td><td rowspan=1 colspan=1>Within±10mg/dL</td><td rowspan=1 colspan=1>Within±15mg/dL</td><td rowspan=1 colspan=1>Within±20mg/dL</td></tr><tr><td rowspan=1 colspan=1>108</td><td rowspan=1 colspan=1>87(80.6%)</td><td rowspan=1 colspan=1>108(100%)</td><td rowspan=1 colspan=1>108(100%)</td><td rowspan=1 colspan=1>108(100%)</td></tr></table>

Accuracy Results for Glucose Concentrations ≥ 75 mg/dL   

<table><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Within ±5%</td><td rowspan=1 colspan=1>Within±10 %</td><td rowspan=1 colspan=1>Within±15 %</td><td rowspan=1 colspan=1>Within±20 %</td></tr><tr><td rowspan=1 colspan=1>492</td><td rowspan=1 colspan=1>261(53.0%)</td><td rowspan=1 colspan=1>413(83.9%)</td><td rowspan=1 colspan=1>467(94.9%)</td><td rowspan=1 colspan=1>488(99.2%)</td></tr></table>

Summary Assessment of Accuracy Readings within ISO Minimum Acceptable Performance Criterion (±15 mg/dL $i f < 7 5$ mg/dL, $\pm 2 0 \%$ if ≥75 mg/dL)

<table><tr><td>596 of 600 (99.3%)</td></tr><tr><td></td></tr></table>

The ISO 15197 standard specifies that at least $9 5 \%$ of readings should fall within $\pm 2 0 \%$ of the standing comparison method for levels $\ge 7 5 ~ \mathrm { m g / d L }$ and within $\pm 1 5$ $\mathrm { m g / d L }$ for levels $< 7 5 ~ \mathrm { m g / d L }$ , and this limit is highlighted in all plots. The system meets the ISO 15197 criterion of at least $9 5 \%$ of readings falling within $\pm 2 0 \%$ (or $\pm 1 5 \mathrm { m g / d L }$ at levels below $7 5 ~ \mathrm { m g / d L } )$ of the sponsor’s comparative method, the YSI Stat Plus Glucose Analyzer.

$b$ . Matrix comparison: See Method Comparison section above.

3. Clinical studies: a. Clinical Sensitivity: Not Applicable.

b. Clinical specificity: Not Applicable.

c. Other clinical supportive data (when a. and b. are not applicable):

Capillary Blood

Performance of the blood glucose monitoring system with capillary blood specimens and an assessment of the User Guide and Quick Reference Guide to show how well untrained subjects could perform a fingerstick, obtain an accurate blood glucose measurement, and perform control solution assays was examined at one site by 109 subjects with diabetes. Health care professionals (HCP) tested in parallel. Meters referenced to whole blood and plasma laboratory glucose and three test strip lots were used. The blood glucose results obtained with the system by the subjects and health care professionals were compared to laboratory glucose results using linear regression and are summarized below.

<table><tr><td rowspan=1 colspan=3>Capillary Fingerstick vs. YSI</td></tr><tr><td rowspan=1 colspan=3>glucose range 75-397 mg/dLhematocrit: 31-59%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Lay User</td><td rowspan=1 colspan=1>HCP</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>108</td><td rowspan=1 colspan=1>108</td></tr><tr><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>0.9585</td><td rowspan=1 colspan=1>0.9479</td></tr><tr><td rowspan=1 colspan=1>y-intercept</td><td rowspan=1 colspan=1>3.7876</td><td rowspan=1 colspan=1>6.4176</td></tr><tr><td rowspan=1 colspan=1>$r2}$</td><td rowspan=1 colspan=1>0.9661</td><td rowspan=1 colspan=1>0.9674</td></tr></table>

# Alternate Site Testing

For alternate site testing, the average of two fingertip test results with the system was used as the comparative method for all alternative site lancing results. A hematocrit determination for each subject was performed from fingertip blood. Results using linear regression are summarized below:

<table><tr><td rowspan=1 colspan=3>AST vs. Fingerstick</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Palm</td><td rowspan=1 colspan=1>Forearm</td></tr><tr><td rowspan=1 colspan=1>glucose range:</td><td rowspan=1 colspan=1>41-374 mg/dL</td><td rowspan=1 colspan=1>39-394 mg/dL</td></tr><tr><td rowspan=1 colspan=1>hematocrit:</td><td rowspan=1 colspan=1>31-53%</td><td rowspan=1 colspan=1>31-53%</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>47</td></tr><tr><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>0.9993</td><td rowspan=1 colspan=1>1.0126</td></tr><tr><td rowspan=1 colspan=1>y-intercept</td><td rowspan=1 colspan=1>2.5104</td><td rowspan=1 colspan=1>-7.8537</td></tr><tr><td rowspan=1 colspan=1>$r^2 }$</td><td rowspan=1 colspan=1>0.9721</td><td rowspan=1 colspan=1>0.9497</td></tr></table>

# Neonatal Blood

Performance of the system with neonatal blood specimens was examined by health care professionals (HCP) at 2 sites using blood samples from 124 subjects (for the regression calculation 2 samples were removed as outliers meeting the NCCLS guideline for outliers: Method Comparison and Bias Estimation Using Patient Samples (EP9-A)). Three test strip lots were used. The blood glucose results obtained with the system were compared to laboratory glucose results. Results using linear regression are summarized below:

<table><tr><td rowspan=1 colspan=2>Neonatal vs. YSI</td></tr><tr><td rowspan=1 colspan=2>glucose range: 27-131 mg/dL</td></tr><tr><td rowspan=1 colspan=2>hematocrit: 27-70%</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>122</td></tr><tr><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>1.0065</td></tr><tr><td rowspan=1 colspan=1>y-intercept</td><td rowspan=1 colspan=1>-0.0522</td></tr><tr><td rowspan=1 colspan=1>$^2}$</td><td rowspan=1 colspan=1>0.8952</td></tr></table>

The sponsor also demonstrated that these results met the ISO accuracy criteria of $9 5 \%$ of the meter results for all lots falling within $\pm 1 5 \mathrm { m g / d L }$ for samples $< 7 5 ~ \mathrm { m g / d L }$ and within $\pm 2 0 \%$ for specimens $> 7 5 ~ \mathrm { m g / d L }$ of a laboratory reference method. Results are summarized in the tables below.

AGREEMENT OF NURSERY SAMPLES TO THE SITE LABORATORY GLUCOSE METHODS   

<table><tr><td rowspan="2"></td><td rowspan="2"></td><td colspan="3">Results Within Given Limits of the Laboratory Glucose Method</td></tr><tr><td>±7.5 mg/dL or 10%</td><td>±15 mg/dL or 20%</td><td>±22.5 mg/dL or 30%</td></tr><tr><td>Test Strip Lot 05M26A</td><td>Meter Reference Plasma</td><td>79.5% (35/44)</td><td>97.7% (43/44)</td><td>97.7% (43/44)</td></tr><tr><td>05M26B</td><td>Plasma</td><td>73.8% (31/42)</td><td>97.6% (41/42)</td><td>97.6% (41/42)</td></tr><tr><td>06A30A</td><td>Plasma</td><td>71.1% (27/38)</td><td>89.5% (34/38)</td><td>100% (38/38)</td></tr><tr><td>Combined</td><td>Plasma</td><td>75.0% (93/124)</td><td>97.6% (121/124)</td><td>98.4% (122/124)</td></tr></table>

Thirty-two samples were obtained (based on the average of the laboratory analyzer results) ranging from $1 0 { - } 5 0 \ \mathrm { m g / d L }$ . The table below shows that the Contour system’s accuracy is adequate for samples ranging from $1 0 { - } 5 0 \ \mathrm { m g / d L }$ , meeting ISO accuracy criteria of $9 5 \%$ of the meter results for all lots falling within $\pm 1 5 \mathrm { m g / d L }$ for samples $<$ $7 5 \mathrm { m g / d L }$ and within $\pm 2 0 \%$ for specimens $> 7 5 ~ \mathrm { m g / d L }$ of a laboratory reference method.

AGREEMENT OF NURSERY SAMPLES TO THE SITE LABORATORY GLUCOSE METHODS - Specimens 10 to 50 mg/dL   

<table><tr><td rowspan="2"></td><td rowspan="2">Meter</td><td colspan="3">Results Within Given Limits of the Comparative Glucose Method</td></tr><tr><td>±7.5 mg/dL or 10%}$</td><td>±15 mg/dL oro 20%}</td><td>±22.5 mg/dL or 30%</td></tr><tr><td>Test Strip Lot Combined</td><td>Reference Plasma</td><td>68.8% (22/32)</td><td>96.9% (31/32)</td><td>96.9% (31/32)</td></tr></table>

The Contour’s meter bias was compared to the hematocrit level for each blood specimen. Correlation coefficients were determined using linear regression shown in the table below.

<table><tr><td rowspan="2">Plasma or WB</td><td colspan="5">Slope</td><td rowspan="2">Intercept 95% C.I.</td><td rowspan="2">Intercept 95% C.I.</td><td rowspan="2">Sy.x</td><td rowspan="2">Correlation Coefficient</td></tr><tr><td>Strip Lot</td><td>Site</td><td>N</td><td>Slope</td><td>(mg/dL)</td></tr><tr><td>Plasma</td><td>All lots</td><td>1&amp;2</td><td>122</td><td>0.44</td><td>0.14 to 0.73</td><td>-21.76</td><td>-37.4 to -6.12</td><td>11.47</td><td>0.255</td></tr></table>

Since the sponsor’s neonatal clinical samples did not cover the claimed range of the meter, contrived samples were used to test the low and high ranges at high levels of Hematocrit. These studies are fond in the above in the Analytical Specificity section.

# Venous Blood

Performance of the system with venous blood specimens was examined at one site by a medical technologist who measured the glucose in 169 samples. Venous blood samples were collected into tubes containing heparin. The material assayed in this study consisted of excess volume that remained after routine laboratory blood work had been completed. Plasma and whole blood referenced meters and three test strip lots were used. The glucose concentration in the samples was adjusted, as necessary, to span the operating range of the system. Results were compared to glucose results obtained at the site with a laboratory analyzer. Results using linear regression are summarized below:

<table><tr><td rowspan=1 colspan=2>Venous Blood vs. YSI</td></tr><tr><td rowspan=1 colspan=2>glucose range: 12-609 mg/dL</td></tr><tr><td rowspan=1 colspan=2>hematocrit: 15-53%</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>169</td></tr><tr><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>0.8927</td></tr><tr><td rowspan=1 colspan=1>y-intercept</td><td rowspan=1 colspan=1>3.614</td></tr><tr><td rowspan=1 colspan=1>r2}$</td><td rowspan=1 colspan=1>0.9884</td></tr></table>

The bias of results is within the ISO accuracy limits of $\pm 1 5 \mathrm { m g / d L }$ or $20 \%$ of the laboratory glucose method. The results are shown below.

<table><tr><td rowspan=1 colspan=3>Median Differences From The Laboratory Method</td></tr><tr><td rowspan=1 colspan=1>Lot</td><td rowspan=1 colspan=1>&lt;75 mg/dL (n=26)</td><td rowspan=1 colspan=1>≥ 75 mg/dL (n=143)</td></tr><tr><td rowspan=1 colspan=1>05M26A</td><td rowspan=1 colspan=1>-2.0mg/dL</td><td rowspan=1 colspan=1>-7.4%</td></tr><tr><td rowspan=1 colspan=1>05M26B</td><td rowspan=1 colspan=1>-2.0 mg/dL</td><td rowspan=1 colspan=1>-8.3%</td></tr><tr><td rowspan=1 colspan=1>06A30A</td><td rowspan=1 colspan=1>-3.0 mg/dL</td><td rowspan=1 colspan=1>-11.0%</td></tr></table>

4. Clinical cut-off: Not Applicable.

5. Expected values/Reference range:

The sponsor included the following Expected Values for normal glucose levels in their meter’s user manual:

<table><tr><td>Status</td><td>Range (mg/dL)</td></tr><tr><td>Before meals</td><td>90-130</td></tr><tr><td>2 hours after meals</td><td>&lt;180</td></tr></table>

American Diabetes Association: Standards of Medical Care in Diabetes (Position Statement). Diabetes Care 29 (Suppl. 1):S10, 2006.

# N. Instrument Name:

Ascensia $^ \mathrm { \textregistered }$ CONTOUR $^ \mathrm { \textregistered }$ Blood Glucose Monitoring System

# O. System Descriptions:

1. Modes of Operation: Each test strip is single use and must be replaced with a new strip for additional readings.

2. Software: FDA reviewed applicant’s Hazard Analysis and software development processes for this line of product types in k023657 and updated functions in this submission.

3. Specimen Identification:

There is no sample identification function with this device. Samples are applied directly to the test strip as they are collected.

4. Specimen Sampling and Handling:

This device is intended to be used with capillary whole blood from the finger, the palm, or the forearm only. Since the whole blood sample is applied directly to the test strip there are no special handling or storage issues.

5. Calibration:

Calibration of the meter occurs by insertion of the test strip and the meter’s recognition of the strip configuration.

6. Quality Control:

The sponsor provides a glucose control solution with the test strips. The meter recognizes the sample as a control solution which prevents control results from being stored in the internal memory. An acceptable range for each control level is printed on the test strip vial label and box. The user is referred to the troubleshooting section of the owner’s manual if control results fall outside these ranges.

P. Other Supportive Instrument Performance Characteristics Data Not Covered In The “Performance Characteristics” Section above:

# Q. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# R. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.